Special issue, focusing on the generic versus branded debate that has opened up post the government mandate that Doctors should online prescribe generics.

Managing Or Gardening? Great Managers Are Like Gardeners: Cultivating Growth in Teams

A great manager is not just a leader; they...

Raja Reddy – 7 Thinking Patterns that Shaped My Career

Raja Reddy is presently the head of marketing at Servier...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?

A quiet but revolutionary milestone may be unfolding in...

AI and the Future of Pharma Field Sales: Boon or Bane?

India’s pharmaceutical industry runs on the strength of its...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Marketing

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?

A quiet but revolutionary milestone may be unfolding in...

AI and the Future of Pharma Field Sales: Boon or Bane?

India’s pharmaceutical industry runs on the strength of its...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Policies/Sales

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?

A quiet but revolutionary milestone may be unfolding in...

AI and the Future of Pharma Field Sales: Boon or Bane?

India’s pharmaceutical industry runs on the strength of its...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Strategy

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?

A quiet but revolutionary milestone may be unfolding in...

AI and the Future of Pharma Field Sales: Boon or Bane?

India’s pharmaceutical industry runs on the strength of its...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Thought Leadership
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Deep Bhandari: Human capital holds the highest value for organizations

DigiStorm 2018 was held on 11 September at the Lalit Ashok in Bangalore. The event was headlined by Prabir Jha – President & Global Chief People Officer, Cipla. Deep Bhandari – Editorial Board Member, MedicinMan, gives us the highlights of the post-lunch session.

Customer Engagement and Experience are the New Differentiators

At the IDMA Marketing and Sales Conference in Mumbai...

Interview with Salil Kallianpur

MedicinMan announces workshops on Digital Marketing in Pharma and Sales Force Excellence.

Boehringer Ingelheim India focuses on partnerships in NCD management

Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”

Is Pharma’s Business Model like McDonald’s? ...

Is Pharma’s business model like McDonald’s? Doing things over & over again without innovation? McDonald’s is famous for its Hamburger University, a training facility at the McDonald’s Corporation global headquarters in Chicago, Illinois. It instructs high-potential restaurant managers in restaurant management. More than 5,000 students attend Hamburger University each year and over 275,000 people have graduated with a degree in Hamburgerology. Sound familiar? Pharma’s training has been on similar lines – hire people continuously and put them through the grind of mugging up essentials of drugs for diseases that the particular company sells. While the McDonald’s model is ideal for its business of replication, it has outlived its utility in healthcare and drug companies are in danger of being reduced to mere suppliers of drugs to new digital platform businesses unless they learn to innovate.